PD-1 Monoclonal Antibody Combined With Gemcitabine and Cisplatin Followed by Selective Radiotherapy for Unresectable Locally Recurrent NPC

NCT07528183 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

86

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancinoma (NPC)

Interventions

DRUG: PD-1 monoclonal antibody combined with gemcitabine and cisplatin followed by selective radiotherapy

Sponsor

Sun Yat-sen University